NASDAQ$ARQT
Arcutis Biotherapeutics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Arcutis reported financial results for the quarter ended March 31, 2021 and provided a business update.
Arcutis had a productive first quarter of 2021, with positive Phase 3 results for topical roflumilast cream in plaque psoriasis and progress in advancing topical roflumilast foam into Phase 3 development for scalp psoriasis and seborrheic dermatitis. The company's Phase 1/2b study of ARQ-252 in chronic hand eczema did not meet its primary endpoint. Arcutis ended the quarter with a strong financial position, holding over $440 million in cash, cash equivalents, and marketable securities.
- NDA submission for topical roflumilast cream as a potential treatment for plaque psoriasis anticipated in the second half of 2021.
- Positive Phase 3 results for topical roflumilast cream in plaque psoriasis announced in February.
- Topical roflumilast foam is advancing into Phase 3 development for the treatment of scalp psoriasis with a single pivotal trial.
- Pivotal Phase 3 trials of topical roflumilast cream in atopic dermatitis were initiated in January.
Headline financials
Revenue & EPS history
Arcutis · Revenue · Quarterly
$0
Forward guidance
Arcutis believes that its current cash, cash equivalents and marketable securities will be sufficient to fund its operations well into 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+1.8%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-0.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+27.2%
Q3 2025
Best reaction
-15.6%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.2% | -9.3% | -9.4% | |
| Q4 2025 | +5.7% | -12.6% | -21.4% | |
| Q3 2025 | +27.2% | +28.9% | +57.6% | |
| Q1 2025 | -4.6% | +0.5% | +0.3% | |
| Q4 2024 | +8.4% | +5.2% | +28.9% | |
| Q3 2024 | +11.8% | +16.6% | +33.3% | |
| Q2 2024 | -14.6% | -13.1% | +7.1% | |
| Q1 2024 | +15.6% | +15.1% | +16.9% | |
| Q4 2023 | +7.4% | +21.5% | +2.3% | |
| Q3 2023 | +5.4% | -0.9% | -10.4% | |
| Q2 2023 | -2.0% | -6.5% | -21.0% | |
| Q1 2023 | -15.6% | -29.3% | -29.8% | |
| Q4 2022 | +4.4% | -2.7% | -31.8% | |
| Q3 2022 | +0.6% | +3.1% | -8.4% | |
| Q2 2022 | +13.2% | +11.8% | +8.6% | |
| Q1 2022 | -11.8% | -14.1% | -3.5% | |
| Q4 2021 | +1.1% | +12.6% | +10.7% | |
| Q3 2021 | -7.5% | -6.9% | -35.6% | |
| Q2 2021 | +3.1% | +5.2% | +4.1% | |
| Q1 2021 | -3.4% | -1.8% | -23.1% | |
| Q4 2020 | -0.1% | +3.6% | -10.5% | |
| Q3 2020 | -3.8% | +8.9% | +37.1% | |
| Q2 2020 | +1.7% | +1.8% | -6.5% | |
| Q1 2020 | +0.0% | -4.6% | -4.6% | |
| Q4 2019 | +0.0% | -4.6% | -4.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro